To examine whether chronic kidney disease (CKD) at any stage is associated with fracture risk after adjusting for competing mortality and to determine whether age or race modify the relationship between CKD and fracture risk. DESIGN: Prospective cohort study. SETTING: Department of Veterans Affairs (VA) national healthcare system. PARTICIPANTS: Men receiving VA primary care aged 65 and older with no history of fracture or osteoporosis therapy (N = 712, 918). MEASUREMENTS: We determined CKD stage from baseline estimated glomerular filtration rate (eGFR). Participants were followed for up to 10 years for occurrence of any fracture or death. We ascertained fractures and covariates from VA medical records and Medicare claims. RESULTS: Of the 356,459 older veterans with CKD (defined as eGFR <60 mL/min per 1.73 m 2 ), 15.7% (n = 56,032) experienced a fracture, and 43.0% (n = 153,438) died over a median time at risk of 5.2 years. Veterans with CKD Stages 3 to 5 had a greater risk of death than those without CKD, which biased estimates from traditional survival models. Competing risk models showed that Stage 3 CKD was associated with greater hazard (adjusted subdistribution hazard ratio (sdHR) = 1.07, 95% confidence interval (CI) = 1.02-1.11) of fracture (than those without CKD) and a trend toward greater hazard for Stage 4 (sdHR = 1.07, 95% CI = 0.94-1.22) and Stage 5 (sdHR = 1.31, 95% CI = 0.97-1.77) CKD. Age, race, and bone mineral density did not modify the relationship between CKD and fracture risk. CONCLUSIONS: In older male veterans, CKD, including Stage 3, is associated with a moderately greater fracture risk irrespective of age, race, or bone mineral density. J Am Geriatr Soc 2018.
O steoporotic fractures are a major source of morbidity, mortality, and cost in older adults. Because fracture risk increases exponentially with age, multimorbidity is the norm for most older adults and can complicate assessment of the risks and benefits of osteoporosis screening and treatment. One of the most common but understudied such comorbidities is chronic kidney disease (CKD).
Older adults with CKD have a greater risk of death at worsening levels of kidney function than those without CKD. 1 Because impaired kidney function reduces bone quality and increases risk of falls, CKD has also been associated with fractures, [2] [3] [4] [5] [6] [7] although prior studies did not take into account competing mortality risk, which can bias fracture risk prediction. Furthermore, it is unknown whether CKD in an older adult with mild, age-related decline in kidney function independently increases the risk of fracture or whether the presence of CKD is merely a marker of other chronic illnesses associated with fracture. Precise estimates of the risk of fracture at all levels of CKD, accounting for competing mortality risk and other risk factors, are therefore needed. Finally, we have insufficient evidence to understand whether race or ethnicity modifies the fracture risk associated with CKD. This is especially important because CKD disproportionately affects African Americans, who generally have a lower fracture risk than Caucasians.
Despite the increasing prevalence of CKD in older adults, current fracture prediction tools, such as FRAX, Garvan, and the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) system, [9] [10] [11] [12] do not include a measure of kidney function, or CKD level, as a risk factor. It is important for clinicians to understand the effect of various CKD levels on fracture risk when making treatment decisions. Therefore, we examined the extent to which various kidney function levels were associated with fracture risk when accounting for competing mortality risk.
METHODS

Study Design
We conducted a retrospective cohort study of male veterans aged 65 and older receiving primary care in the Department of Veterans Affairs (VA) health system between January 1, 2000, and December 31, 2010. We used merged data from VA medical records (including inpatient files, outpatient files, laboratory and pharmacy data) and Medicare claims (Parts A and B) to ascertain clinical characteristics, fractures, and deaths. The Durham VA institutional review board approved this study.
Study Population
This cohort was a subgroup of a larger population-based retrospective cohort study designed to evaluate osteoporosis screening in male veterans. In the parent study, the analytical sample included men aged 65 and older who received primary care at a VA Medical Center equipped to conduct dual x-ray absorptiometry (DXA) screening between 2000 and 2010. Veterans with prior diagnoses of osteoporosis, any fractures (defined as presence of any International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) fracture codes, excluding skull, facial, digital, and pathological fractures), or evidence of bisphosphonate use during a 3-year look-back period were excluded. For this analysis, we also excluded veterans with missing creatinine values during a 3-year look-back period. Using these selection criteria, we identified 356,459 older veterans with CKD, defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73 m 2 on at least 2 occasions at least 3 months apart ( Figure 1 ). We selected this cohort of veterans with prevalent CKD to represent what clinicians would be likely to encounter in clinical practice. Prevalent CKD is more accurately identifiable in administrative data than incident CKD and allows time for CKD-related bone abnormalities to manifest. 13 For analytical efficiency, we selected a random sample of equal size of subjects without CKD to include in our cohort.
Variables
We assessed for the occurrence of fractures or death from the start of the observation period, defined as the date of a subject's first primary care visit after DXA became available in their facility, through December 31, 2010. Fracture events and types were determined from ICD-9 and CPT codes from inpatient and outpatient encounters in our merged dataset. We assessed death uisng the National Death Index and the VA Benefits Identification Records Locator Subsystem death file.
Our primary exposure variable was kidney function as measured according to eGFR. We calculated eGFR from the Modification of Diet in Renal Disease equation using VA laboratory data between 3 years before and after a subject's start date. In the absence of other markers of kidney damage (e.g., abnormal urine composition, kidney imaging test), we used eGFR alone to classify the cohort into four clinically relevant categories: no or mild CKD (eGFR ≥60.0 mL/min per 1.73 m . We identified covariates associated with fracture or death from clinical data assessed at baseline. These variables included participant demographic characteristics (age, race), region of residence, body mass index (BMI), and additional fracture risk factors listed below. We used ICD-9 and CPT codes from inpatient and outpatient VA and Medicare claims, supplemented with prescription medication use and laboratory values as appropriate, to identify the presence of specific fracture risk factors. To enhance accuracy in identification of each risk factor, these codes had to be identified at two or more visits (inpatient or outpatient) or at one visit accompanied by a relevant prescription for treatment of the risk factor (when applicable). The fracture risk factors included smoking, chronic glucocorticoid use, androgen deprivation therapy, chronic alcohol abuse, rheumatoid arthritis, hyperthyroidism, diabetes mellitus, chronic obstructive pulmonary disease, chronic liver disease, and malabsorption disorder. Additional details regarding operational definitions for these fracture risk factors are available upon request.
Statistical Analysis
We used the FRAX tool with BMI to calculate each subject's 10-year probability of major fracture. 10 In the subset of participants in whom bone mineral density (BMD) was assessed during routine care, results were extracted using a validated natural language processing tool, 14 and FRAX with BMD was also calculated. FRAX scores, along with all other study variables, were reported as proportions for categorical variables and means with standard deviations or medians with interquartile ranges for continuous variables. For descriptive purposes, we conducted bivariate analyses using a 4-level ordinal CKD group definition based on eGFR (described above), with the reference group being no CKD (eGFR ≥ 60.0 mL/min per 1.73 m 2 ), and each covariate using analysis of variance for continuous variables and chi-square tests for categorical variables, with appropriate contrasts to compare each CKD level with the reference group. To evaluate the hazards of fracture attributable to each CKD group, we used Cox proportional hazards regression models, adjusting for demographic characteristics (except for age), region, BMI, and fracture risk factors (listed above). Because cohort members enter the observation period at different ages, data were left-truncated, and age served as the time-toevent scale. 15 Using the Cox models, we performed tests for interaction between eGFR subgroups and baseline age groups (65-74, 75-84, ≥85) and race (Caucasian, African American, other (Asian or Hispanic ethnicity)). To account for the competing risk of death, we used the Fine and Gray method to estimate unadjusted and multivariable adjusted subdistribution relative hazards of fracture. 16 After confirming the proportional hazards assumption, we performed an additional competing risk analysis adjusting for BMD in cohort members with available BMD data. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Cohort Characteristics
Our analytical sample included 712,918 male veterans (Figure 1 ). Of the 356,459 subjects with CKD, 95.2% (n = 339,278) of cohort members had Stage 3 CKD, 4.3% (n = 15,167) Stage 4, and 0.5% (n = 2,014) Stage 5. Cohort members without CKD were younger and less likely to have chronic alcohol use, hyperthyroidism, diabetes, chronic obstructive pulmonary disease, chronic liver disease, and malabsorption disorders and had lower FRAX-BMI scores (Table 1) .
Fracture and Death Events
Over a median follow-up of 5.2 years, 14.1% (n = 100,254) of cohort members experienced fractures; 12.4% (n = 44,223) of those without CKD and 15.7% (n = 56,031) of those with CKD. The three most common sites of fracture in those with CKD were hip or femur (25.8%, n = 14,452), rib or clavicle (22.6%, n = 12,640), and vertebra (16.9%, n = 9,489) (Supplementary Table S1 ). Overall mortality over follow-up was 35.5% (n = 253,415). In adjusted analyses, Stage 3 CKD was associated with slightly greater hazard of death (hazard ratio (HR) = 1.05, 95% confidence interval (CI) = 1.03-1.08) than no CKD. There was a stepwise increase in hazards of death for Stage 4 CKD (HR = 2.07, 95% CI = 1.94-2.20) and Stage 5 CKD (HR = 2.48, 95% CI = 2.12-2.91).
Association Between CKD and Fracture Risk with and without Competing Mortality
Survival curves demonstrated that the rate of fracture events increased with worsening kidney function (Figure 2-dotted lines) . Tests for interaction showed that older age and race did not modify the association between CKD and fracture. In analyses adjusting for fracture risk factors and censoring for death, cohort members with Stage 3 CKD had a significantly lower risk of fracture (HR = 0.95, 95% CI = 0.92-0.99) at any point in the observation period than those without CKD ( Accounting for the competing risk of death changed the risk estimates for all levels of kidney function (Figure 2) . Specifically, Stage 3 CKD was associated with greater hazard (adjusted subdistribution HR (sdHR) = 1.07, 95% CI = 1.02-1.11) of fracture than no CKD. Stage 4 CKD was also associated with greater hazard (sdHR = 1.07, 95% CI = 0.94-1.22) of fracture than no CKD. Accounting for the high competing risk of death in Stage 4 or 5 CKD (60% died during the observation period) attenuated the association seen in the Cox regression models but still demonstrated a trend toward greater fracture risk (Table 2 ). When FRAX-BMD was added to a competing risk model with eGFR alone for the subset of patients in whom it was available (n = 36,563), the strength of association between eGFR and fracture was relatively unchanged, indicating that the addition of BMD to the model did not mediate the association between eGFR and fracture.
DISCUSSION
It is estimated that 20% to 33% of older adults worldwide will develop osteoporotic fractures, 17, 18 and at least 25% of older adults will also develop CKD in their lifetime. 19 With the high prevalence of osteoporosis and CKD in older adults, it is important for clinicians and researchers to understand how CKD at various stages modifies the risk of fracture. We demonstrated that even moderate (Stage 3) CKD remained associated with fracture risk even in the face of competing mortality.
Our findings demonstrate the importance of considering the competing risk of mortality when estimating the effect of CKD on fracture risk. Most existing observational studies that show an association between CKD and fracture risk did not account for competing mortality and limited analyses to hip fractures. 2, 4 One population-based study that performed competing risk analyses found an 83% greater risk of death and 16% greater risk of hip fracture in individuals with CKD diagnoses, and the risk of hip fracture was mildly attenuated to 14% in competing risk models. 7 Adding to this evidence, we examined the association between each CKD stage and risk of any fracture in the face of competing risk of mortality. Although we had a smaller sample of participants with Stage 4 CKD, the effect size was identical to that for Stage 3 CKD (HR = 1.07). Thus, our study provides further evidence that high mortality seen in CKD does not preclude strategic fracture risk prediction and management in these individuals, including those with Stage 3 CKD.
Our findings have implications for osteoporosis screening. Current U.S. practice guidelines recommend DXA screening in men aged 65 and older who have one or more fracture risk factors, but the American College of Physicians Male Osteoporosis Screening Guideline, 20 the Endocrine Society Osteoporosis in Men Guideline, 21 and the Veterans Affairs Male Osteoporosis Screening Algorithm 22 do not commonly consider CKD to be a fracture risk factor Similarly, in the United Kingdom, guidelines recommend that decisions to pursue DXA screening be determined from FRAX (with BMI) estimates of fracture risk, but the FRAX tool does not include a measure of kidney function. 23 The magnitude of the greater risk we observed, especially for Stage 4 and 5 CKD, is comparable with that of well-accepted risk factors, including smoking, chronic lung disease, and chronic liver disease. 24, 25 We identified this greater risk of fracture attributable to CKD, including Stage 3 CKD, despite the inherent limitations of the Modified Diet in Renal Disease estimating equation that cause overestimation of eGFR in older adults. 26, 27 This would tend to bias our analysis against finding a significant effect of Stage 3 CKD, making our positive findings even more compelling. Because many people with Stage 3 CKD will progress to later stages, in which treatment options are more limited, and our results suggest that even moderately reduced kidney function is associated with greater fracture risk after controlling for traditional fracture risk factors, such men should be considered for DXA screening. Although men with advanced CKD may not be screened because of concerns about competing mortality risk yielding insufficient time to benefit, our results support screening selected men with advanced CKD given that their fracture risk remains high after considering the competing risk of mortality. Further research is needed to develop a clinical prediction tool to help clinicians identify men with advanced CKD who may benefit from DXA screening.
Our findings also have implications for osteoporosis treatment in older adults with CKD. Current guidelines recommend osteoporosis treatment for men and women with a 10-year probability of hip fracture of 3% or greater or of major osteoporosis-related fracture of 20% or greater. 28 This fracture risk assessment does not consider level of kidney function. We found that level of kidney function, as measured using eGFR, is associated with greater fracture risk independent of BMD. The fact that altered vitamin D metabolism resulting in renal osteodystrophy has a greater effect on bone quality, which DXA does not measure, than on bone density may explain this finding in part. The independent risk of fracture attributable to eGFR could modify treatment decisions. For example, the FRAX tool calculates that a 79-year-old male smoker with a parental history of hip fracture and a BMI of 22.8 kg/m 2 has a 10-year risk of major osteoporotic [30] [31] [32] [33] but additional data regarding benefits and side effects are needed to inform the treatment of older adults with Stage 3 or more-advanced CKD. 34 This study's strength derives from its large population-based cohort of male veterans, although administrative data lack important information and introduce study limitations. First, we did not optimally classify participants according to level of kidney function because we did not have urine albumin data or other evidence of kidney damage (renal imaging, clinical notes). As a result, there may have been misclassification of some subjects with Stage 3 as subjects without CKD, although it is likely that this misclassification error would bias our findings toward no significant difference between these groups. Second, we used clinically diagnosed fractures as our endpoint, which is accurate for most fracture types, but misses up to two-thirds of vertebral fractures. The underdiagnosis of vertebral fractures may be more likely in nonwhite men who tend to access healthcare services less and therefore have less opportunity for vertebral fractures to be diagnosed incidentally during other imaging studies. Third, our models did not capture important unmeasured confounders, such as falls, frailty, comorbidity burden, vitamin D status, and markers associated with secondary hyperparathyroidism (serum parathyroid hormone level, calcium, fibroblast growth factor 23, phosphorus levels). Last, associations based on our cohort of male veterans who receive primary care in the VA may not be fully generalizable to the larger population of older men and women with CKD or individuals younger than 65.
Older adults with Stage 3 CKD have a greater risk of any fracture than those without CKD when accounting for competing risk of mortality. Attention to moderate CKD as an independent fracture risk factor could improve osteoporosis screening and treatment decisions. Sponsor's Role: The National Institutes of Health (and other sponsors) did not have any role in study design; data collection, analysis, or interpretation; or manuscript preparation.
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